RJA
AKBA icon

Raymond James & Associates’s Akebia Therapeutics AKBA Stock Holding History

Raymond James & Associates’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$55.9K Sell
42,311
-8,928
-17% -$11.9K ﹤0.01% 3843
2024
Q2 		$52.3K Buy
51,239
+10,000
+24% +$12.4K ﹤0.01% 3790
2024
Q1 		$75.5K Buy
41,239
+11,322
+38% +$18.1K ﹤0.01% 3765
2023
Q4 		$37.1K Buy
29,917
+9,696
+48% +$9.89K ﹤0.01% 3733
2023
Q3 		$23.1K Buy
20,221
+8,619
+74% +$11.1K ﹤0.01% 3723
2023
Q2 		$10.6K Buy
+11,602
New +$11.2K ﹤0.01% 3808
2022
Q3 		– Sell
-12,900
Closed -$5K – 3942
2022
Q2 		$5K Hold
12,900
– – ﹤0.01% 3970
2022
Q1 		$9K Sell
12,900
-10,500
-45% -$22.5K ﹤0.01% 4064
2021
Q4 		$53K Buy
23,400
+1,005
+4% +$2.74K ﹤0.01% 3937
2021
Q3 		$64K Hold
22,395
– – ﹤0.01% 3892
2021
Q2 		$85K Buy
22,395
+224
+1% +$754 ﹤0.01% 3861
2021
Q1 		$75K Buy
22,171
+1,800
+9% +$6.48K ﹤0.01% 3815
2020
Q4 		$57K Buy
20,371
+9,750
+92% +$28.5K ﹤0.01% 3613
2020
Q3 		$27K Sell
10,621
-4,645
-30% -$40.8K ﹤0.01% 3493
2020
Q2 		$207K Buy
15,266
+1,331
+10% +$13.8K ﹤0.01% 3112
2020
Q1 		$106K Sell
13,935
-2,374
-15% -$18.5K ﹤0.01% 3203
2019
Q4 		$103K Sell
16,309
-5,043
-24% -$24K ﹤0.01% 3473
2019
Q3 		$84K Buy
21,352
+1,852
+9% +$7.94K ﹤0.01% 3406
2019
Q2 		$94K Buy
+19,500
New +$111K ﹤0.01% 3415
2018
Q3 		– Sell
-38,698
Closed -$386K – 3638
2018
Q2 		$386K Sell
38,698
-63
-0.2% -$631 ﹤0.01% 2853
2018
Q1 		$369K Sell
38,761
-798
-2% -$11.2K ﹤0.01% 2757
2017
Q4 		$588K Buy
39,559
+2,721
+7% +$45.1K ﹤0.01% 2428
2017
Q3 		$725K Buy
36,838
+321
+0.9% +$4.93K ﹤0.01% 2276
2017
Q2 		$525K Buy
36,517
+519
+1% +$6.58K ﹤0.01% 2382
2017
Q1 		$331K Buy
35,998
+2,184
+6% +$21.3K ﹤0.01% 2633
2016
Q4 		$352K Buy
33,814
+5,068
+18% +$43.6K ﹤0.01% 2542
2016
Q3 		$260K Buy
28,746
+5,809
+25% +$49.4K ﹤0.01% 2708
2016
Q2 		$172K Sell
22,937
-228
-1% -$1.99K ﹤0.01% 2702
2016
Q1 		$209K Sell
23,165
-764
-3% -$6.2K ﹤0.01% 2554
2015
Q4 		$309K Buy
+23,929
New +$244K ﹤0.01% 2181

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's AKBA Position: Q3 2024 in Review

Raymond James & Associates reduced its Akebia Therapeutics (AKBA) stake by 17% in Q3 2024, selling an estimated $11.9K and leaving 42,311 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3843.

Raymond James & Associates first reported a position in AKBA in Q4 2015 and has held it in 30 quarters since. The position peaked at $725K in Q3 2017. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • Raymond James & Associates held 42,311 shares of Akebia Therapeutics worth $55.9K as of Q3 2024.
  • Raymond James & Associates sold 8,928 Akebia Therapeutics shares in Q3 2024, an estimated $11.9K.
  • Akebia Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3843 holding.
  • Raymond James & Associates first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 30 quarters since.
  • Raymond James & Associates's Akebia Therapeutics position peaked at $725K in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.